Abstract
The Recent Trend in Bio-Similar Drugs Development
Highlights
Bio-Similar is the fastest growing field of pharmaceutical industries
The Pharmacovigilance is an important soul for the extra knowledge and for the safety data for the Bio-Similar due to the
Traceability and proactive risk management is very important for the knowledge about the safety of the Bio-Similar and the immunogenicity is important
Summary
Bio-Similar is the fastest growing field of pharmaceutical industries They were produced mainly by (Recombinant DNA technology-antibody/monoclonal body’s technologies). This has provided many cures and prevention to some life Dangerous illness such as Diabetes, rheumatoid arthritis, cancer, inflammatory etc. This has produced a wide range of product like growth hormone, insulin, recombinant vaccines and gene cloning product. Bio-Similars are approved based on part on the studies done with the reference product. It is possible to produce a specific mAb to almost any extracellular/cell surface target, indicated by the ubiquitous amount of research and development currently being conducted to generate monoclonal antibodies against numerous diseases that are difficult to treat by drug therapy or surgery.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Global Journal of Pharmacy & Pharmaceutical Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
